Anthem Biosciences IPO ends today, subscribed 8.31x; GMP at ₹156

The bidding window for the Anthem Biosciences IPO closes today, July 16, 2025, with allotment expected to be finalised by Thursday, July 17. The IPO is slated for listing on both the BSE and NSE, with a tentative listing date of Monday, July 21. The total issue size is ₹3,395 crore, entirely comprising an offer for sale of 5.96 crore shares. The price band is fixed at ₹540–₹570 per share, and the minimum lot size is 26 shares, requiring a minimum investment of ₹14,040. Leading financial institutions including JM Financial, Citigroup Global Markets India, JP Morgan India, and Nomura are acting as the book-running lead managers, while Kfin Technologies is the registrar.

As of Day 3, the IPO has been subscribed 8.39 times overall, with the retail investor segment subscribing 3.59 times, Qualified Institutional Buyers (QIB) 5.22 times, and Non-Institutional Investors (NII) 23.89 times. However, since the issue is entirely an offer for sale, the company will not receive any proceeds. All funds raised will go to the promoter selling shareholders, after adjusting for offer-related expenses and applicable taxes.

According to a Livemint report on July 16, the grey market premium (GMP) for Anthem Biosciences stood at ₹156, indicating a potential listing price of around ₹726—suggesting a possible listing gain of approximately 27.37% over the issue price. It's important to note that GMP is unofficial and speculative; investors should conduct their own research before making any decisions.

Founded in 2006 and based in Bengaluru, Anthem Biosciences is a prominent Contract Research, Development & Manufacturing Organization (CRDMO) that provides end-to-end services in drug discovery, development, and manufacturing for small molecules and biologics. The company serves over 550 clients in 44 countries, with a significant presence in regulated markets like the US, Europe, and Japan. In FY25, Anthem posted a revenue of ₹1,844.6 crore and a net profit of ₹451.3 crore, reflecting strong financial performance and industry positioning.